INTRODUCTION

The oligo-metastatic state is conventionally an intermediate state that, even though the disease must be considered systemic, may beneft from local treatments. Evidence of the benefit from aggressive local therapies comes from improved survival in retrospective series and randomised trials.

The advent of more sophisticated imaging techniques has allowed to diagnose earlier and deliver progressively higher doses to small target volumes with ablative intent stereotactic body radiation therapy (SBRT).

This webinar aims to highlight the role of SBRT in oligometastatic patients and in combination with chemotherapy, target therapies and immunotherapy in the most common diseases (breast, lung, prostate).

After a brief introduction of all the aspects of the oligometastatic setting, the combination scenario of drugs and SBRT will be presented from two main points of view: the Radiation oncologist’s vs the Medical oncologist’s one.

CME Provider

Istituto Europeo di Oncologia S.r.l.
CME Provider (n. 207) e Segreteria Scientifica
Ieoedu.eventi@ieo.it

With the Endorsement of


The webinar is fully funded by Associazione Italiana per la Ricerca sul Cancro (AIRC), project IG-14300 “Carbon ions boost followed by pelvic photon intensity modulated radiotherapy for high-risk prostate cancer”, registered at ClinicalTrials.gov (NCT02672449), approved by IEO R86/14-IEO 98.

Organising Secretariat

MZ Congressi S.r.l.
Tel: 02 66802323 3421863400
Ieoedu.eventi@ieo.it